Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 1/20 | 0.53 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2962712 | 0.91 | FUCA1 (0.58) | FUCA1S1PR1S1PR5GAASIGMAR1 | |
| SCHEMBL1514852 | 0.84 | FUCA1 (0.55) | FUCA1S1PR1S1PR5GAASIGMAR1 | |
| SCHEMBL30875889 | 0.84 | FUCA1 (0.55) | FUCA1S1PR1S1PR5GAASIGMAR1 | |
| SCHEMBL20417932 | 0.84 | FUCA1 (0.55) | FUCA1S1PR1S1PR5GAASIGMAR1 | |
| SCHEMBL18339637 | 0.84 | FUCA1 (0.55) | FUCA1S1PR1S1PR5GAASIGMAR1 | |
| SCHEMBL19518531 | 0.84 | FUCA1 (0.55) | FUCA1S1PR1S1PR5GAASIGMAR1 | |
| SCHEMBL17560348 | 0.84 | FUCA1 (0.55) | FUCA1S1PR1S1PR5GAASIGMAR1 | |
| SCHEMBL31327374 | 0.84 | FUCA1 (0.55) | FUCA1S1PR1S1PR5GAASIGMAR1 | |
| SCHEMBL9265205 | 0.82 | TACR1 (0.47) | FUCA1S1PR1S1PR5GAASIGMAR1 | |
| SCHEMBL6201908 | 0.81 | ACHE (0.53) | SIGMAR1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6589934-B1 | Methods of treatment of non insulin dependent diabetes mellitus, antagonists of the delayed rectifier potassium channel Kv2.1, methods of using and preparing the antagonists and assays for identifying such antagonist | SMITHKLINE BEECHAM CORPORATION | 2003-07-08 | — | — | US | disclosed |
| EP-1042322-B1 | Kv2.1 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2002-04-17 | — | — | EP | disclosed |
| EP-1042322-A1 | Kv2.1 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999032487-A1 | Kv2.1 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 1999-07-01 | — | — | WO | disclosed |